All In Biotech

Drug Trial Radar · NCT05160415

A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy

A Phase 1b, Open-label Study of the Safety and Pharmacokinetics of EDG-5506 in Adults With Becker Muscular Dystrophy

Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

12

Actual

Start

Dec 28, 2021

Primary completion

Mar 1, 2024

Study completion Mar 1, 2024

Sponsor

Lead sponsor
Edgewise Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Medpace, Inc.
First posted
Dec 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The ARCH study was an open-label, single-center, Phase 1b study of sevasemtem (EDG-5506) to assess the safety and pharmacokinetics (PK) of sevasemten in adults with Becker muscular dystrophy (BMD). Sevasemten is an investigational product intended to protect and improve function of dystrophic muscle fibers.

Conditions

  • Becker Muscular Dystrophy

Interventions

  • SevasemtenDrug

    Daily oral dose of 10 mg daily until Visit 8 (Day 57), followed by 15 mg daily until Visit 13 (Month 6), followed by 20 mg until Visit 21 (Month 15), followed by 10 mg daily to Visit 27 (Month 24).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Treated With Sevasemten Experiencing AEsTime frame: From first dose of study drug to 25 months
  2. Frequency of AEs in Those Treated With SevasemtenTime frame: From first dose of study drug to 25 months
  3. Number of Participants Treated With Sevasemten With AEs by Maximum SeverityTime frame: From first dose of study drug to 25 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rare Disease Research

    Atlanta, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.